Emotional moment ‘kind' Davina McCall meets girl, 11, who has brain tumour just like she did
TV star Davina McCall cheers a brain tumour girl as they chat about their treatment.
Davina had hers removed on the day Kirsty Waugh, 11, was diagnosed.
4
4
4
Kirsty's parents Mat and Kate noticed the coincidence and asked if the 57-year-old star could send a supportive message.
Davina obliged, and also visited the family in Tunbridge Wells, Kent.
Mat said: 'She is as lovely and generous as you'd hope.
'There was lots of laughing and hugging.'
Kirsty's 70 weeks of chemo are starting to shrink the tumour.
She can read and watch films again.
Mat said: "Davina had her brain tumour removed on the same day that Kirsty was admitted to hospital and diagnosed.
"She is local to us so I wondered if we could get a message from her.
"They talked a lot about their respective cancer treatment.
"It was a really uplifting experience. We all felt better for having spoken to her.
Watch emotional moment Davina McCall breaks down in tears and says 'I'm still here' in first interview after brain surgery
4
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
To Exist as I am by Grace Spence Green: Don't ignore me - and don't pity me, either
To Exist as I am: A Doctor's Notes on Recovery and Radical Acceptance by Grace Spence Green (Wellcome £16.99, 244pp) On October 17, 2018 Grace Spence Green, 22, a fourth-year medical student, was walking through the atrium of Westfield Shopping Centre in east London towards the tube station when a stranger jumped head first from the top-floor balcony and landed on her neck. The fact that she happened to be walking past at that moment meant Grace broke the man's fall and thus saved his life. But his fall broke her spinal cord. She was paralysed for life, from the chest down. The two would never exchange words. She doesn't even mention the man's name in this powerful and excoriating memoir. On the night of the accident, he happened to be in the bay beside hers in A&E, just for one night. Much later, she discovered he was a migrant who'd been high on weed. He was sentenced to four years in jail for grievous bodily harm, released after serving two, and then deported. She doesn't feel bitterness towards 'The Man', as she calls him, or even any emotional connection. All of her anger, and there's a great deal of it, is directed towards us, the general public, for getting things so wrong in what we say to disabled people, and how we treat them. Prepare to be severely chastened – and re-educated. Grace says she doesn't desire our insatiable curiosity, or our pity, yet she invokes both, strongly, in her visceral account of the aftermath of that fateful day. The week in a high-dependency unit 'in a warm, fuzzy, opioid dream'; the 26 metal staples put down the middle of her back by the surgeon Dr Bull; the eeriness of the 'bloodless injury', which nonetheless wrecked her body; the ominous words spoken by the doctors three months later, at the official prognosis and diagnosis meeting: 'It would be good to see things changing over the next few weeks.' But things did not change. Sensation did not come back to her legs or toes. Up to then, part of her still believed that the operation would 'fix' her, and make everything go back to how it was before. Now, 'my seemingly impenetrable bubble of denial had burst'. It would take eight months for the fact that the injury was permanent, and that she would never walk again, to sink fully into her brain. At the Royal National Orthopaedic Rehabilitation Centre in Stanmore, north-west London, Grace was relieved as well as shocked to meet other young people in a similar plight. There was competitiveness among some of the patients. 'Are you walking yet?' she was asked. 'Not yet,' she'd reply. She recalls the bleakness of returning to the Centre after a few days at home over Christmas with her loving family and her steadfast boyfriend Nathan, to whom she would later become engaged. She thought back to the weekend before the accident: she and her friends had sat up all night round a bonfire in a Kentish field, chatting and laughing. 'Now I find I have lost control of every bodily function, in a place I cannot leave.' She was told she'd need to insert a single-use catheter into herself every four hours for the rest of her life. She felt 'waves of hatred' towards the wheelchair at first – until she learned to appreciate it as a tool, just as spectacles are a tool. She now can't stand the expression 'wheelchair-bound'. She bristles when people use the word 'inspirational' to describe her progress – she calls it 'inspiration porn', as if people get some kick from her 'tragic' story. 'I've heard the word so many times that it's lost all meaning.' But it's hard not to see her as an inspiration. She completed her medical studies, became a junior doctor in 2021 and now makes it her business to protect the dignity and autonomy of her patients, in a way that sometimes did not happen to her. She notices that as soon as she takes off her lanyard and stethoscope at the end of the working day, she becomes 'hyper-visible and utterly ignored'. That's the daily status of too many disabled people. She does not like her wheelchair to be pushed or pulled 'in the name of helping'. It undermines her autonomy. She also hates it when people hold the door open for her: 'It can be much easier for me to do it myself, rather than having to duck under an outstretched arm.' We should say to a disabled person, 'You let me know if you need help.' Questions and remarks that annoyed her while she was in hospital were: 'Is there anything that can be done?'; 'Are you getting better?'; and 'It's not permanent, I hope?' So, don't say those. But also, whatever you do, don't say to a disabled person that you don't see them as disabled. ' 'You're not looking at me properly,' I want to say. 'You are missing a huge part of me by trying to ignore this." ' And on no account must you say you pity her. 'When people do that, it feels as if they have forced their way into my world and spat on it.' Nor must you single a disabled person out for notice, even out of kindness. Once, back at medical school, an instructor was on the phone cross that a lesson was starting late. 'And we have a lady in a WHEELCHAIR waiting in the corridor, so it's just unacceptable.' Grace felt 'shaken, to be singled out in a crowd of peers.' Later, the instructor said, 'Sorry – I'm really sorry, I didn't mean to be offensive, I'm sorry, it was just a stressful situation.' Grace didn't 'interrupt her ramble'. She just looked directly into her eye and said, 'OK'. 'Micro-aggression upon microaggression, piling up,' Grace calls all this. For her, it's an uphill battle to defend her happiness, when the assumption is that she's the 'poor brave tragic girl', whose boyfriend was 'a hero' not to desert her. Every October 17, she celebrates her 'alive day'. The fact that her wheelchair is full of scratches and dents is a sign of a life lived to the full. 'I am going to enjoy a life that society has told me is not worthy. That is activism.'
The Independent
2 hours ago
- The Independent
NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside
Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced. The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies. Approximately 1,500 patients annually with multiple myeloma, an incurable bone marrow cancer, are expected to benefit from this new treatment. The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS. NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be available to patients whose cancer has advanced or has not responded to initial treatments. Administered as an infusion every three weeks alongside other cancer drugs, this antibody drug targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
The Guardian
2 hours ago
- The Guardian
Sickle cell patients to have quicker and more accessible treatment in England
People living with sickle cell disease in England are to benefit from quicker and more accessible treatment due to a £9m investment, the government has announced. Apheresis services, which are a type of treatment that removes harmful components from a patient's blood, are to improve across England through the funding of more specialist treatment centres. The funding will ensure the wider availability of machines that remove a patient's sickled red blood cells and replace them with healthy donor cells. More than 20 NHS trusts currently offer Spectra Optia technology, a treatment more effective than blood transfusions and having been shown to be highly effective in reducing complications such as iron overload. The investment could save the NHS up to £12.9m every year thanks to a reduction in time spent in hospital for patients and the reduced need for other treatments, according to the government. Sickle cell disease primarily affects people from an African-Caribbean background. In England, about 17,000 people are living with the disease, an inherited blood disorder, with 250 new cases a year. Wes Streeting, the health and social care secretary, said: 'People living with rare conditions like sickle cell disease face immense everyday challenges, and can sometimes struggle to get the specialised care they need. 'To make our health service fit for the future, we have to harness the power of new technologies, and these machines provide a shining example of how our government is starting to make huge advancements in digital healthcare. 'Through our plan for change, this government will be the one that removes the barriers to getting the latest and best tech to our NHS frontline, so patients can access the best care available, closer to home.' Prof Bola Owolabi, the director of healthcare inequalities at NHS England, said: 'This is great news for people living with sickle cell disease – a condition that disproportionately affects Black African and Black Caribbean communities. 'Sickle cell patients have needed new treatment options for decades and this additional funding will provide greater access to this life-changing technology which has the potential to significantly improve patients' quality of life.' Owolabi added that sickle cell care in England continued to be among the best in the world, with England the first country to introduce a groundbreaking gene-editing therapy, which offers a functional cure to the disease. Sign up to First Edition Our morning email breaks down the key stories of the day, telling you what's happening and why it matters after newsletter promotion 'Alongside this important step, the recent approval of a new gene-editing therapy for patients with severe sickle cell disease showcases the NHS's clear commitment to improving outcomes for the 17,000 people living with the condition in England,' Owolabi said. John James, the chief executive of the Sickle Cell Society, said: 'We are delighted to see the arrival of this long-overdue funding, which will improve access to vital treatment for people living with sickle cell disorder and their families. 'This announcement follows years of collaboration between the Sickle Cell Society and the NHS, and we're pleased that this investment will help make access to care fairer, more consistent, and far less stressful for many individuals.'
